Crucell, BIOA&D Co. Ltd. deal

CRXL granted BIOA&D a license to use the PER.C6 cell line to produce adenoviral vectors expressing constituted endothelial nitric oxide synthase (ceNOS) to treat cardiovascular disease. Separately, B...